Table 2 Medication profile
From: A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's disease
Group | Non Hallucinators | Hallucinators |
|---|---|---|
| Â | N = 39 | N = 31 |
L-dopa | 38 (97.4%) | 30 (96.8%) |
Dopamine Agonist | 25 (64.1%) | 18 (58.1%) |
Amantadine | 9 (23.1%) | 7 (22.6%) |
Anticholinergics | 4 (10.3%) | 4 (12.9%) |
COMT inhibitors | 7 (17.9%) | 4 (12.9%) |
MAO-B inhibitors | 2 (5.1%) | 3 (9.7%) |
Cholinesterase inhibitors | 4 (10.3%) | 1 (3.2%) |
Antipsychotics* | 0 | 5 (16.1%) |
Antidepressants | 12 (30.8%) | 11 (35.5%) |